Rxsight Inc (RXST) Investment Analysis:
1. Executive Summary
RxSight, Inc. (NASDAQ: RXST) is a commercial-stage ophthalmic medical device company focused on the development and commercialization of post-operatively adjustable intraocular lenses (IOLs) for patients undergoing cataract surgery [cite: 1, 2]. The company’s core innovation—the RxSight Light Adjustable Lens (LAL® and LAL+®) platform—is the first and only technology approved by the U.S. Food and Drug Administration (FDA) that enables surgeons to non-invasively adjust and customize a patient’s visual acuity after surgical implantation [cite: 1, 2, 3].
RxSight generates revenue through three primary commercial channels:
1. Consumable Lenses (LAL / LAL+ / LAL Toric): High-margin sales of proprietary, photosensitive silicone intraocular lenses directly to Ambulatory Surgery Centers (ASCs) and specialized outpatient surgical centers where cataract procedures are performed [cite: 1, 2, 4, 5].
2. Capital Equipment (Light Delivery Device - LDD™): Sales and leases of office-based light delivery consoles to ophthalmic practices [cite: 1, 2, 4]. The LDD console delivers precise, low-intensity ultraviolet (UV) light patterns to modify the optical power of previously implanted LALs during routine follow-up visits [cite: 2, 6].
3. Strategic Collaboration Revenues: Revenue recognized through commercial partnerships, headlined by a non-exclusive license and co-development agreement established with Alcon Inc. in July 2026 to develop light-adjustable presbyopia-correcting intraocular lenses (PCIOLs), bringing up to $200 million in upfront and milestone payments alongside future commercial sales royalties [cite: 3, 5, 7, 8].
Geographically, RxSight operates predominantly in the United States, which generates the vast majority of net revenue, while selectively expanding its commercial footprint into international markets following regulatory approvals in territories such as Australia [cite: 4, 6]. The primary customers are ophthalmic surgeons, private eye care practices, and ASCs [cite: 4]. The core end market is the premium refractive cataract market, where patients pay out-of-pocket co-payments for advanced lens technologies that offer freedom from spectacles [cite: 2, 9, 10].
Surgeons and patients choose RxSight over traditional fixed-power premium IOLs (such as diffractive multifocal or extended-depth-of-focus lenses) because conventional lenses rely on pre-operative biometry and corneal measurements that are subject to surgical healing variations [cite: 2, 6, 11]. This pre-operative estimation frequently results in residual refractive error, glare, or unwanted optical aberrations [cite: 6, 11]. RxSight’s post-operative adjustability eliminates pre-operative guesswork by allowing clinicians to fine-tune spherical and astigmatic vision to match the patient’s real-world visual preferences after the eye has fully healed, resulting in high rates of uncorrected visual acuity and patient satisfaction [cite: 6, 11].
2. Business Drivers & Strategic Overview
Product and Service Detail
The RxSight Light Adjustable Lens system integrates two proprietary commercial components designed to work in tandem throughout the post-surgical patient care cycle:
- Light Adjustable Lens (LAL / LAL+ / LAL Toric): A foldable, photosensitive silicone intraocular lens implanted during standard phacoemulsification cataract surgery [cite: 1, 2]. The lens matrix incorporates proprietary photo-reactive silicone macromers uniformly distributed throughout its structure [cite: 2]. When exposed to targeted UV light patterns delivered by the LDD console, these macromers undergo local photopolymerization [cite: 2]. This process creates a spatial concentration gradient that prompts unreacted macromers to diffuse into the illuminated area, changing the physical shape and refractive power of the lens in vivo [cite: 2]. The LAL+ variant incorporates a modified optical profile to extend the depth of focus, providing intermediate vision enhancement alongside distance sharpness [cite: 1, 2, 5].
- Light Delivery Device (LDD): An office-based light projection system featuring integrated spatial light modulators, diagnostic imaging, and precise beam-steering optics [cite: 1, 2, 4]. Following lens implantation and surgical recovery, clinicians administer 1 to 3 non-invasive light treatments (lasting 60–90 seconds each) spaced several days apart to adjust spherical and cylindrical power [cite: 2, 6]. Once desired visual acuity is achieved, a final "lock-in" light exposure is applied to consume all remaining macromers, permanently fixing the lens's optical profile [cite: 2, 6].
- Next-Generation Platform Development: RxSight is currently advancing a next-generation platform designed to streamline post-operative treatment protocols, significantly reducing the required number of office visits and lowering practice adoption friction [cite: 3, 5].
Moat Analysis
RxSight possesses a multi-layered economic moat encompassing intellectual property protection, capital equipment switching costs, regulatory entry barriers, and expanding strategic ecosystem partnerships:
- Intellectual Property & Regulatory Barriers: RxSight maintains an extensive international patent portfolio covering photopolymer chemistry, light-guided refraction algorithms, and spatial beam projection systems [cite: 2, 12, 13]. As a Class III medical device approved through the FDA Premarket Approval (PMA) process, any prospective competitor would require 5 to 8 years of clinical trials and substantial capital investment to bring a competing light-adjustable platform to market [cite: 1, 6]. RxSight remains the only FDA-approved post-operatively adjustable IOL platform available commercially [cite: 2, 3, 7].
- High Switching Costs & Installed Base Capital Lock-In: The LDD console represents a meaningful capital investment for an ophthalmic practice [cite: 1, 4]. Once a clinic purchases an LDD, integrates treatment protocols, and trains clinical staff, the practice is operationally and financially incentivized to maximize LAL procedure volume [cite: 1, 4, 6]. Replacing the platform would render the capital equipment investment obsolete and disrupt established practice workflows.
- Ecosystem Advantage via Alcon Collaboration: The strategic non-exclusive agreement established with Alcon Inc. in July 2026 enhances RxSight's economic moat [cite: 3, 7, 14]. Combining RxSight’s adjustable technology with Alcon’s presbyopia-correcting optical designs validates RxSight's core technology, provides access to Alcon's global distribution footprint, and supplies up to $200 million in non-dilutive capital milestones ($60 million upfront/near-term) [cite: 3, 7, 8].
Total Addressable Market (TAM) & Market Opportunity
Over 30 million cataract procedures are performed globally each year, including approximately 4.5 million annual surgeries in the United States. Historically, premium IOL penetration—where patients pay out-of-pocket for advanced optical functionality—has hovered between 15% and 20% of total cataract volume [cite: 9]. However, demographic trends and active aging lifestyles are projected to expand premium lens adoption toward 30% to 40% over the next decade [cite: 9].
RxSight’s immediate addressable market spans the premium cataract and refractive lens exchange sectors, representing a U.S. TAM exceeding $1.5 billion and a global market opportunity exceeding $3.5 billion. As post-operative adjustability expands into presbyopia-correcting optics through the Alcon alliance, RxSight’s platform becomes applicable across nearly the entire premium intraocular lens market [cite: 7, 14].
Competitive Landscape
RxSight competes within the broader ophthalmic surgical market alongside established multinational medtech firms:
- Alcon Inc.: Markets market-leading premium IOL platforms, including the Clareon PanOptix trifocal lens and the AcrySof IQ Vivity extended-depth-of-focus lens [cite: 7].
- Johnson & Johnson Vision: Offers the Tecnis family of lenses, including Tecnis Synergy, Tecnis Multifocal, and Tecnis Eyhance.
- Bausch + Lomb & Carl Zeiss Meditec: Supply specialized premium optics, toric lenses, and standard monofocal lenses.
Traditional premium IOLs rely on fixed pre-operative optical configurations. While diffractive multifocal lenses offer spectacle independence, they can cause loss of contrast sensitivity, night glare, and halos, often requiring secondary laser enhancements or surgical lens exchanges [cite: 6, 11]. RxSight is positioned as the sole platform offering post-surgical customization to eliminate unpredictable outcomes [cite: 2, 3, 7]. The July 2026 strategic alliance with Alcon shifts RxSight's dynamic with the industry leader from direct competition to high-margin co-development [cite: 3, 7, 14].
3. Financial Performance & Valuation
Latest Reported Quarterly Results (Q2 2026)
- Reporting Date: August 5, 2026 (for the second quarter ended June 30, 2026) [cite: 3, 15, 16].
- Total Net Revenue: $33.7 million, compared to $35.0 million in Q2 2025 product revenue [cite: 3, 4, 15, 16]. Total Q2 2026 revenue includes $27.2 million in direct product sales and $6.5 million in recognized collaboration revenue under the Alcon agreement [cite: 3, 5, 15, 16].
- Product Volume Breakdown: Product sales comprised [cite: 5, 15, 16]:
- Light Adjustable Lens (LAL / LAL+): 24,917 units sold [cite: 15, 16].
- Light Delivery Device (LDD): 12 capital units placed (reflecting a deceleration in new practice capital sales compared to prior quarters) [cite: 4, 11, 15, 16].
- Gross Margin Performance: Consolidated gross margin reached 76.7% (with product gross margin at 74.9%), expanding year-over-year due to a favorable shift toward high-margin consumable LAL sales and high-margin collaboration revenue recognition [cite: 16, 17].
- Net Performance & EPS: GAAP Net Loss was $(12.10) million, or $(0.29) per basic and diluted share [cite: 16]. Non-GAAP Adjusted Net Loss stood at $(4.63) million [cite: 16].
- Liquidity & Balance Sheet: Cash, cash equivalents, and short-term investments totaled $208.8 million as of June 30, 2026, providing a solid liquidity balance with minimal debt obligations [cite: 9, 15, 16, 17].
Earnings Beats/Misses & Guidance Guidance Pivots
In Q1 2026 (announced May 2026), RxSight beat consensus estimates, reporting $30.9 million in revenue (exceeding expectations by 3.87%) and an EPS of -$0.19 (beating expectations of -$0.31) [cite: 9].
On July 6, 2026, alongside the Alcon strategic collaboration disclosure, RxSight updated its full-year 2026 outlook to $140.0 million–$160.0 million in total revenue ($110.0M–$120.0M product sales plus $30.0M–$40.0M collaboration revenue) [cite: 5]. However, on August 5, 2026, during the Q2 2026 earnings release, newly appointed CEO Aziz Mottiwala announced that management withdrew full-year 2026 financial guidance while the executive team conducts a thorough commercial assessment, with formal guidance expected to resume in early 2027 [cite: 3, 18].
Executive Commentary & Strategic Realignments
In July 2026, RxSight enacted a key executive transition: Aziz Mottiwala was named President and CEO, while former CEO Dr. Ron Kurtz transitioned to Chief Medical Officer [cite: 3, 19, 20]. CFO Shelley Thunen had previously resigned in January 2026 [cite: 2].
CEO Aziz Mottiwala noted that while clinical satisfaction with LAL remains high, capital placement rates (LDD unit sales) slowed as early-adopter practices completed initial hardware adoption [cite: 3, 4, 6, 11]. To address this, management is restructuring commercial field operations into a unified "Customer Success Organization," refocusing sales teams on driving procedure utilization across the existing installed base rather than relying heavily on capital equipment sales [cite: 4].
Analyst Reactions & Market Impact
The combination of slowing LDD sales, C-suite restructuring, and the withdrawal of 2026 guidance led to several sell-side price target reductions in late 2026 [cite: 3, 18, 21, 22]. Consensus price targets were lowered to approximately $7.57–$7.79 per share [cite: 21, 22, 23]. The equity experienced significant downward re-rating, moving from a 52-week high of $13.09 toward $5.02 USD [cite: 21, 22, 24].
Historical Financial Performance Table
| Financial Metric |
FY 2023 |
FY 2024 |
FY 2025 |
Q2 2026 (Quarterly) |
| Total Net Revenue |
$89.1M [cite: 25] |
$139.9M (+57% YoY) [cite: 25, 26] |
$132.6M (-5% YoY) [cite: 6] |
$33.7M (inc. $6.5M collab) [cite: 15, 16] |
| Gross Margin % |
65.5% [cite: 11] |
70.7% [cite: 11] |
76.6% [cite: 6, 11] |
76.7% [cite: 16, 17] |
| GAAP Net Loss |
$(27.5)M [cite: 26] |
$(48.6)M [cite: 26] |
$(38.9)M [cite: 11] |
$(12.1)M [cite: 16] |
| LAL Units Sold |
~54,700 units |
98,055 units (+79%) [cite: 25] |
109,615 units (+12%) [cite: 1, 6] |
24,917 units [cite: 15, 16] |
| LDD Installed Base |
666 units [cite: 10, 26] |
971 units (+46%) [cite: 10, 26] |
1,134 units [cite: 1, 6] |
1,134+ units [cite: 1, 15] |
| Cash & Investments |
$182.6M [cite: 26] |
$237.2M [cite: 27] |
~$227.5M [cite: 27] |
$208.8M [cite: 15, 16] |
4. Risk Assessment & Macroeconomic Considerations
Execution Risks
- Commercial Field Re-organization: Transitioning sales teams into a Customer Success Organization requires a pivot from capital equipment pitching to clinical utilization support [cite: 4]. Operational disruption during this sales realignment could lead to temporary weakness in LAL re-order rates across key clinical practices [cite: 4].
- C-Suite Leadership Transition: With CEO Aziz Mottiwala assuming leadership following the CFO's exit, management turnover presents near-term execution and strategy alignment risks [cite: 2, 3, 20].
Competitive & Technology Risks
- Alternative Premium Optical Designs: Competitors such as Alcon and Johnson & Johnson Vision continue to launch fixed-power premium lenses that do not require post-operative light adjustment appointments [cite: 7, 9]. If fixed optics improve significantly or rival adjustable technologies emerge, practice interest in light adjustments could moderate [cite: 9].
Operational & Customer Demand Risks
- Post-Operative Patient Visit Burden: Standard LAL protocols require patients to wear protective UV eyewear post-surgery and return to the clinic for 2 to 4 light treatment sessions [cite: 2, 6]. Scheduling constraints and patient compliance regarding extra clinic visits represent a hurdle to broader practice adoption [cite: 3, 5, 6].
Regulatory, Legal & Capital Risks
- Class III FDA Post-Approval Commitments: RxSight must maintain compliance with ongoing FDA post-approval study (PAS) requirements [cite: 1, 6]. Any clinical non-compliance or adverse post-market surveillance findings could lead to regulatory warnings or restricted labeling [cite: 1].
- Balance Sheet Runway: Annual operating cash burn averages approximately $30M–$40M. However, RxSight's $208.8 million cash balance provides several years of liquidity, mitigating near-term insolvency or highly dilutive capital raising risks [cite: 9, 15, 16, 27].
Macroeconomic Sensitivities
- Consumer Out-of-Pocket Discretionary Spending: Premium IOLs require out-of-pocket patient co-payments of $1,500 to $3,000 per eye above basic insurance coverage. In inflationary or challenging economic environments, elective patient upgrades to premium lenses can slow as consumers opt for standard monofocal lenses covered by insurance [cite: 4, 9].
Strategic Risk Evaluation Framework
The potential operational risks facing RxSight follow a distinct continuum of severity and impact:
- What Could Go Wrong: LDD console placements stall, existing practices underutilize installed LDD consoles, or the Alcon co-development effort experiences technical delays [cite: 3, 6, 7].
- Early Warning Signs: Sequential declines in LAL unit volume per installed LDD, gross margin contraction below 70%, or increased turnover within the commercial field force [cite: 4, 6, 9, 11].
- What Would Most Damage the Long-Term Thesis: A formal termination of the Alcon strategic collaboration agreement, or the clinical entry of a rival light-adjustable lens platform that bypasses RxSight’s intellectual property portfolio [cite: 3, 7].
5. 5-Year Scenario Analysis
To establish a valuation framework over a 5-year horizon (through 2031), three operational scenarios are modeled based on underlying business drivers and revenue trajectories.
- Baseline Valuation Inputs (Year 0 / late 2026):
- Current Share Price: $5.02 USD [cite: 22, 24, 28].
- Shares Outstanding: 41.59 million [cite: 16, 17].
- Market Capitalization: ~$208.8 million USD [cite: 22].
- Net Cash Position: ~$208.8 million USD (~$5.02 cash per share) [cite: 15, 16, 22].
Scenario Descriptions & Operating Assumptions
1. Base Case (55% Probability)
- Operational Narrative: CEO Aziz Mottiwala successfully realigns the commercial organization, expanding LAL procedure volume across the 1,134+ LDD installed base [cite: 1, 3, 4, 20]. LAL consumable unit volumes grow at a 16.0% CAGR through 2031, supported by international expansion and next-gen platform adoption [cite: 3, 5, 6]. The Alcon co-developed light-adjustable PCIOL achieves commercial launch in 2028, generating high-margin milestone and royalty revenue [cite: 3, 7, 8].
- Financial Model (Year 5 / 2031):
- Total Net Revenue: $310.0 million (reflecting an 18.0% 5-year revenue CAGR from 2026 levels).
- Operating Margin: Reaches 18.0% as high-margin consumable sales and royalties leverage sales overhead.
- Net Income: $55.8 million (assumes a 21% effective corporate tax rate).
- Diluted Share Count: 44.0 million shares.
- Earnings Per Share (EPS): $1.27 USD.
- Valuation & Projected Outcome: A 18.0x exit P/E multiple applied to 2031 EPS yields a projected share price of $22.86 USD.
2. High Case / Bull (25% Probability)
- Operational Narrative: Rapid adoption of the next-generation workflow platform eliminates multi-visit patient friction, accelerating LAL utilization rates across eye care clinics [cite: 3, 5]. The Alcon co-developed light-adjustable PCIOL becomes a standard premium lens option globally [cite: 3, 7, 14].
- Financial Model (Year 5 / 2031):
- Total Net Revenue: $464.0 million (28.0% 5-year revenue CAGR).
- Operating Margin: Expands to 26.0% due to substantial operating leverage and recurring milestone/royalty streams [cite: 7].
- Net Income: $120.6 million.
- Diluted Share Count: 45.0 million shares.
- Earnings Per Share (EPS): $2.68 USD.
- Valuation & Projected Outcome: A 24.0x exit P/E multiple applied to 2031 EPS yields a projected share price of $64.32 USD.
3. Low Case / Bear (20% Probability)
- Operational Narrative: Practice capacity constraints limit post-operative patient visits, capping LAL procedure adoption [cite: 4, 6]. LDD capital sales remain depressed, and the Alcon co-development project experiences engineering delays [cite: 3, 6, 7].
- Financial Model (Year 5 / 2031):
- Total Net Revenue: $164.0 million (4.0% 5-year revenue CAGR).
- Operating Margin: Remains constrained at 2.0% due to fixed SG&A overhead [cite: 9].
- Net Income: $3.3 million.
- Diluted Share Count: 46.0 million shares.
- Earnings Per Share (EPS): $0.07 USD.
- Valuation & Projected Outcome: A 15.0x operating P/E ($1.05 per share operating value) combined with a net cash asset floor of $3.26 per share yields a projected share price of $4.31 USD.
5-Year Projected Share Price Trajectory
| Scenario |
Year 0 (2026) |
Year 1 (2027) |
Year 2 (2028) |
Year 3 (2029) |
Year 4 (2030) |
Year 5 (2031) |
| High Case (USD) |
$5.02 |
$9.50 |
$18.00 |
$31.00 |
$48.00 |
$64.32 |
| Base Case (USD) |
$5.02 |
$7.00 |
$10.50 |
$14.50 |
$18.50 |
$22.86 |
| Low Case (USD) |
$5.02 |
$4.80 |
$4.60 |
$4.50 |
$4.40 |
$4.31 |
Compact 5-Year Scenario Summary
| Scenario |
Revenue / Key Metric in Year 5 |
Margin / Earnings Assumption |
Valuation Multiple Assumption |
Current Share Price |
Implied Future Share Price |
5-Year Total Return |
Annualized Return |
Probability |
| High Case |
$464.0M Revenue |
26.0% Op Margin ($2.68 EPS) |
24.0x Exit P/E |
$5.02 USD |
$64.32 USD |
+1,181.3% |
+66.5% |
25% |
| Base Case |
$310.0M Revenue |
18.0% Op Margin ($1.27 EPS) |
18.0x Exit P/E |
$5.02 USD |
$22.86 USD |
+355.4% |
+35.4% |
55% |
| Low Case |
$164.0M Revenue |
2.0% Op Margin ($0.07 EPS) |
15.0x P/E + Cash Floor |
$5.02 USD |
$4.31 USD |
-14.1% |
-3.0% |
20% |
| Probability-Weighted |
$328.6M Revenue |
$1.64 Weighted EPS |
Blended Multiples |
$5.02 USD |
$29.51 USD |
+487.8% |
+42.5% |
100% |
HIGH ASYMMETRIC UPSIDE
6. Qualitative Scorecard
-
Management Alignment: 7/10
Newly appointed CEO Aziz Mottiwala was granted performance equity awards comprising 2.31M RSUs and 571k stock options with a $5.19 exercise price, structuring executive compensation around long-term share price recovery [cite: 20, 29].
-
Revenue Quality: 6/10
The business model generates recurring, high-margin consumable lens sales (LALs), but overall revenue consistency is affected by capital equipment sales cycles (LDDs) and patient out-of-pocket spending trends [cite: 1, 4, 6].
-
Market Position: 7/10
RxSight holds an exclusive market position in post-operatively light-adjustable intraocular lenses [cite: 2, 3, 7]. However, near-term market position expansion is constrained by slower capital placement rates across conservative practices [cite: 4, 6, 11].
-
Growth Outlook: 7/10
Growth potential is supported by utilization expansion across the existing LDD installed base, next-generation workflow enhancements, and global co-development with Alcon [cite: 1, 3, 5, 7].
-
Financial Health: 8/10
RxSight maintains a strong balance sheet with $208.8 million in cash and short-term investments and negligible long-term debt liabilities, providing substantial liquidity runway [cite: 9, 15, 16, 17].
-
Business Viability: 8/10
The durability of the platform is supported by over 300,000 completed LAL procedures, FDA post-approval study validation, and commercial backing from industry leader Alcon [cite: 1, 6, 7].
-
Capital Allocation: 7/10
Management demonstrated disciplined capital allocation by securing $60 million in upfront and near-term non-dilutive milestone funding through the Alcon partnership, monetizing its IP while preserving equity capital [cite: 3, 7, 8].
-
Analyst Sentiment: 5/10
Analyst sentiment remains cautious following the withdrawal of 2026 guidance, C-suite changes, and sell-side price target reductions [cite: 3, 21, 22, 23].
-
Profitability: 4/10
While product gross margins are strong at ~75%–77%, ongoing operating cash burn (~$35M–$45M annually) due to R&D and commercial field overhead weighs on near-term net profitability [cite: 6, 16, 17, 27].
-
Track Record: 5/10
RxSight successfully pioneered an entirely new medical device category, though public market performance has experienced valuation volatility following guidance revisions and commercial realignments [cite: 4, 6, 21, 30].
BLENDED QUALITATIVE SCORE: 6.4 / 10
SOLID STRATEGIC FOUNDATION
7. Conclusion & Investment Thesis
RxSight presents an asymmetric fundamental outlook. The equity experienced significant market contraction following the withdrawal of FY 2026 guidance, slowing capital placement rates, and C-suite leadership transitions [cite: 3, 6, 18, 21]. However, the core clinical value proposition—that post-operative adjustability offers superior precision in premium refractive cataract surgery—remains fundamentally intact [cite: 2, 6, 11].
Key catalysts and strategic drivers shaping the company's trajectory include:
1. Commercial Focus under CEO Aziz Mottiwala: Refocusing the commercial sales force toward LAL procedure utilization across the existing 1,134+ LDD installed base directly targets the root cause of recent growth deceleration [cite: 1, 3, 4, 20].
2. Alcon Strategic Co-Development: Partnering with the global leader in eye care validates RxSight's light-adjustable technology, provides $60 million in non-dilutive capital, and creates an international commercial vehicle for adjustable presbyopia-correcting lenses [cite: 3, 7, 8].
3. Valuation Margin of Safety: Trading near its net cash value (~$5.02 cash per share versus a ~$5.02 stock price), the market valuation reflects limited enterprise operating value, establishing meaningful re-rating potential upon commercial stabilization [cite: 15, 16, 22, 24].
TRANSFORMATIONAL PIVOT AHEAD
8. Technical Analysis, Price Action & Short-Term Outlook
RxSight’s stock price (~$5.02 USD) is currently trading near the lower end of its 52-week trading range ($4.51–$13.09), below its 50-day moving average (~$5.91–$6.09) and 200-day simple moving average (~$6.81–$7.38) [cite: 21, 22, 23, 24, 30, 31]. Technical indicators indicate oversold conditions (RSI of ~26–49) alongside negative MACD momentum, driven by sell-side target reductions following guidance withdrawal [cite: 3, 21, 22, 30]. In the short term, share price action is expected to consolidate within the $4.50 to $6.00 USD range as the market awaits management's updated commercial strategy and formal guidance reinstatement in early 2027 [cite: 3, 21, 23].
OVERSOLD CONSOLIDATION PHASE
- RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance, https://investors.rxsight.com/news-releases/news-release-details/rxsight-inc-reports-fourth-quarter-and-2025-results-issues-2026
- DEF 14A - SEC.gov, https://www.sec.gov/Archives/edgar/data/1111485/000119312526187240/rxst-20260427.htm
- RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook, https://investors.rxsight.com/news-releases/news-release-details/rxsight-inc-reports-second-quarter-2026-results-and-provides
- RxSIGHT, INC. - Public Technologies (PUBT), https://docs.publicnow.com/viewDoc.aspx?filename=185252\EXT\D6C55E6DDC23B522BF1182859BFD0A5CA7EA7DAF_6B3B971F33278C8FE186319EE12FB5DCD3666811.PDF
- EX-99.1 - SEC.gov, https://www.sec.gov/Archives/edgar/data/1111485/000119312526296200/rxst-ex99_1.htm
- RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance, https://investors.rxsight.com/news-releases/news-release-details/rxsight-inc-reports-fourth-quarter-and-2025-results-issues-2026/
- Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs, https://www.globenewswire.com/news-release/2026/07/06/3322753/0/en/alcon-and-rxsight-announce-collaboration-to-develop-adjustable-pciols.html
- Alcon, RxSight to develop light-adjustable presbyopia-correcting IOL - Healio, https://www.healio.com/news/ophthalmology/20260708/alcon-rxsight-to-develop-lightadjustable-presbyopiacorrecting-iol
- Earnings call transcript: RxSight beats Q1 2026 forecasts, stock dips - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-rxsight-beats-q1-2026-forecasts-stock-dips-93CH-4665694
- RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance, https://investors.rxsight.com/news-releases/news-release-details/rxsight-inc-reports-fourth-quarter-and-full-year-2024-financial
- 10-K - SEC.gov, https://www.sec.gov/Archives/edgar/data/1111485/000119312526071775/rxst-20251231.htm
- Quarterly Results - Investor Relations - RxSight, https://investors.rxsight.com/financial-information/quarterly-results
- 10-Q - SEC.gov, https://www.sec.gov/Archives/edgar/data/1111485/000095017023019703/rxst-20230331.htm
- Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs, https://investor.alcon.com/news-and-events/press-releases/news-details/2026/Alcon-and-RxSight-Announce-Collaboration-to-Develop-Adjustable-PCIOLs/default.aspx
- RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook, https://www.globenewswire.com/news-release/2026/08/05/3339682/0/en/rxsight-inc-reports-second-quarter-2026-results-and-provides-update-on-2026-outlook.html
- RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook, https://investors.rxsight.com/news-releases/news-release-details/rxsight-inc-reports-second-quarter-2026-results-and-provides/
- RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook, https://www.stocktitan.net/news/RXST/rx-sight-inc-reports-second-quarter-2026-results-and-provides-update-jhka4dcvcg7z.html
- RxSight, Inc. Common Stock (RXST) Historical Quotes - Nasdaq, https://www.nasdaq.com/market-activity/stocks/rxst/historical
- RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Finviz, https://finviz.com/news/308091/rxsight-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026
- RxSight names new CEO and adopts inducement plan | RXST 8-K Filing - Stock Titan, https://www.stocktitan.net/sec-filings/RXST/8-k-rx-sight-inc-reports-material-event-35e1633c0cd8.html
- RxSight, Inc. (RXST) Stock Analysis: Evaluating The 46% Potential Upside In Medical Device Innovation - DirectorsTalk Interviews, https://www.directorstalkinterviews.com/rxsight-inc-rxst-stock-analysis-evaluating-the-46-potential-upside-in-medical-device-innovation/4121262886
- RXST Stock Quote Price and Forecast - CNN, https://www.cnn.com/markets/stocks/RXST
- RxSight, Inc. (RXST) Stock Analysis: Potential 56% Upside And Strategic Position In Medical Devices - DirectorsTalk Interviews, https://www.directorstalkinterviews.com/rxsight-inc-rxst-stock-analysis-potential-56-upside-and-strategic-position-in-medical-devices/4121265754
- The Cooper Companies, Inc. Stock Price: Quote, Forecast, Splits & News (COO) - Perplexity, https://www.perplexity.ai/finance/COO?comparing=COO,CLPT,RXST,AXGN,GKOS,BFLY
- RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance, https://investors.rxsight.com/news-releases/news-release-details/rxsight-inc-reports-fourth-quarter-and-full-year-2024-financial/
- RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance, https://investors.rxsight.com/node/9206/pdf
- 10-Q - SEC.gov, https://www.sec.gov/Archives/edgar/data/1111485/000119312525266986/rxst-20250930.htm
- GKOS Price: Quote, Forecast, Charts & News - Perplexity, https://www.perplexity.ai/finance/GKOS?comparing=GKOS,AXGN,RXST,COO,BFLY,CLPT
- RxSight grants CEO new RSUs and stock options | RXST Insider Trading, https://www.stocktitan.net/sec-filings/RXST/form-4-rx-sight-inc-insider-trading-activity-be2e683ef29a.html
- RxSight, Inc. (RXST) Stock Analysis: Evaluating The 59% Upside Potential Amidst Volatile Performance - DirectorsTalk Interviews, https://www.directorstalkinterviews.com/rxsight-inc-rxst-stock-analysis-evaluating-the-59-upside-potential-amidst-volatile-performance/4121265088
- RxSight, Inc. (RXST) Stock Analysis: Exploring A 49% Upside Potential In The Medical Device Sector - DirectorsTalk Interviews, https://www.directorstalkinterviews.com/rxsight-inc-rxst-stock-analysis-exploring-a-49-upside-potential-in-the-medical-device-sector/4121267571